(Q36011951)

11 August 2017

1 reference

title

Therapeutic modalities in hepatitis C: challenges and development (English)

1 reference

11 August 2017

1 reference

Moreno-Otero R

1

1 reference

11 August 2017

publication date

1 January 2005

1 reference

Journal of Viral Hepatitis

11 August 2017

published in

1 reference

11 August 2017

volume

12

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

10-19

1 reference

Epidemiology of hepatitis C

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

New therapeutic strategies for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Transmissible agent in non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

New animal models of hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Efficient conditional transgene expression in hepatitis C virus cDNA transgenic mice mediated by the Cre/loxP system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Treatment of acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

The treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Hepatic stellate (ITO) cells: expanding roles for a liver-specific pericyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Ribavirin enhances interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Treatment of patients with hepatitis C and normal serum aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Side effects of therapy of hepatitis C and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Impaired health-related quality of life in chronic hepatitis C: the how, but not the why.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Neoadjuvant photodynamic therapy before curative resection of proximal bile duct carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Antibody response to hepatitis B virus vaccination in individuals with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Ribozyme gene therapy for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Interferon plus amantadine versus interferon alone in the treatment of naı̈ve patients with chronic hepatitis C: a UK multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00563.X

10.1111/J.1365-2893.2005.00563.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference